EBAG9 and neoplasm: An inclusive anti-tumor outcome was attained through the multifactorial therapeutic potential of JOL2888: the inhibition of RCAS1 expression enabled T cell immune elicitation, reduced the TAM population, and suppressed the expression of pro-oncogenic genes alongside the inherent tumor specificity and lethality of JOL2888.